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the disease was developed and the study adopted society’s perspective while the
horizon time considered was patient’s remaining lifespan. Cohorts of COPD pa-
tients treated with Tiotropium or cohorts of patients undergoing pulmonary reha-
bilitation programs were simulated (Monte-Carlo simulations in TreeAge software)
and compared to identical cohorts of patients subjected to usual care. Life expec-
tancies, quality adjusted life-years (QALY), disease-related costs, and incremental
cost-utility ratios were estimated. RESULTS: At the horizon of a patient’s remain-
ing lifetime (14.29 life years in average, considering a population combining mod-
erate to very severe patients), tiotropium would result in 0.12 life years and 0.58
QALY gained (mean estimates), induce an additional cost of 5380 €/patient in the
disease-related costs, with a corresponding incremental cost-utility ratio of 8853
€/QALY. For pulmonary rehabilitation programs, these estimates were 0 life years,
0.31 QALY, 2,969 €, and 12,000 €/QALY, respectively. Results were mostly sensitive
to the utility changes associated with exacerbations. CONCLUSIONS: Tiotropium
treatment and pulmonary rehabilitation programs were estimated as worth inter-
ventions in the studied population, below the usual threshold used for declaring
procedures as cost effective. Nevertheless, the modest gains in health issued from
the study emphasize the need of research for developing more effective COPD-
related therapies.
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OBJECTIVES: To assess costs, utilities and cost-utility of fixed combination salme-
terol/fluticasone (SAL/FP maintenance treatment) versus non-fixed combination
budesonide  formoterol in one pack (BUDFORM maintenance treatment) in the
management of patients with bronchial asthma by means of an OPTIMA model.
METHODS: In this analysis we used the following data: drug prices (from List of
Maximum Permissible Manufacturer Prices for Vital and Essential Drugs) and drug
dosage proportion (from MRC Pharmexpert, 4Q 2010); number of inhalations per
day (from instructions); QOL and number of health care resources for controlled
and uncontrolled asthma (from published sources); resource unit costs (from 2010
health care insurance program). Work-off day costs included tax deficiency, GDP
underproduction and sick pay. Frequency of controlled asthma was obtained from
ARROW study (Ogorodova et al., 2009) for SAL/FP (73%) and from FACET trial
(O’Byrne et al. 2008) for BUDFORM (62%). Conceptual formula of analysis was: cost
of drugs% controlled * cost of controlled% uncontrolled * cost of uncontrolled.
One-way sensitivity analysis was conducted to assess the robustness of the results.
RESULTS: Average monthly costs of drugs were 1,677 RUR/€42 and 2,023 RUR/€51
for SAL/FP and BUDFORM respectively. Medical costs and QOL measures were 378
RUR/€9 and 0.75 for controlled asthma; 88,295/€2,207 RUR and 0.49 for uncontrolled
asthma. Yearly total costs per patient were higher for BUDFORM than for SAL/FP
(58,057/€1,451 RUR vs. 44,244 RUR/€1,106). Compared to BUDFORM, SAL/FP was
associated to an expected increase of QALYs per patient (0.68 QALYs vs. 0.65
QALYs). The cost-utility analysis showed that SAL/FP was dominant (less costly
and more effective in terms of QALYs gained). Results were sensitive to all the
parameters varied in the sensitivity analysis, especially health care costs.
CONCLUSIONS: Treatment of patients with bronchial asthma with SAL/FP is a
dominant strategy in comparison with non-fixed combination BUDFORM in one
pack.
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OBJECTIVES: Smoking is the leading cause of preventable death in El Salvador
(50%) and results in many serious comorbidities, including lung cancer, coronary
heart disease, stroke and chronic respiratory disease. The aim of this study was to
evaluate the cost-utility of varenicline compared to other existing strategies for
smoking cessation within a 5-year time horizon in El Salvador using the healthcare
payer’s perspective. METHODS: The Benefits of Smoking Cessation on Outcomes
(BENESCO) simulation model was used for an adult cohort (n4,537,803). Diseases
included were: stroke, lung cancer, coronary heart disease and chronic obstructive
pulmonary disease. Smoking cessation therapies compared were: varenicline (0.5 –
2 mg/day), bupropion (300 mg/day), nicotine replacement treatment (NRT) (5-10
mg/day) and unaided cessation. Effectiveness measure was: quality-adjusted life
year gained (QALY’s), which was obtained from published literature. Resource use
and costs data were obtained from El Salvador’s Ministry of Health and Social
Security official databases (2010). The model used a 3% discount rate for costs
(expressed in 2010 US dollars) and QALYs. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking related morbidity, mortality and healthcare costs. After 5 years,
Varenicline gained 306,158 QALYs, which represents 73, 94 and 178 more QALYs
than bupropion, NRT and unaided cessation, respectively. Overall costs showed
varenicline as the least expensive option against bupropion (US$328,558), NRT
(US$412,730) and unaided cessation (US$777,124). Cost-effectiveness analyses
showed that varenicline was the dominant strategy. Acceptability curves showed
that varenicline would be cost-effective within 3 GDP per capita threshold. PSA
results support the robustness of the findings. CONCLUSIONS: Smoking cessation
therapy with varenicline is cost-saving in El Salvador. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
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OBJECTIVES: To estimate annual medical and productivity costs attributable to
obesity in adult patients with asthma in the US. METHODS: This study used the
2003-2008 Medical Expenditure Panel Survey. Asthma patients(18-64 years) were
identified using ICD-9-CM code 493, clinical classification code-128, or physician
diagnosis. Patients were classified as normal(BMI:18.5-25 kg/m2), overweight-
(BMI:25-30 kg/m2) or obese(BMI:30 kg/m2). Medical costs were estimated using
a generalized linear model(GLM) with a log link function and gamma distribution.
Costs associated with productivity loss were calculated based on missed working
days due to illness and average hourly wage using a two part model. In the first
part, logistic regression was used to estimate the probability of having missed
working days due to illness. In the second part, among patients with missed work-
ing days, GLM was used with the estimated probability from first part of model to
estimate the cost associated with productivity loss. The costs attributable to obe-
sity were estimated by differences between the observed and estimated cost in
obese patients, using a distribution of covariates obtained from normal patients.
All costs were converted to 2010 US dollars using price indices. RESULTS: A total of
8775 adults were identified with asthma. The average treatment cost and lost pro-
ductivity costs of normal patients were $3154(95%CI:$2689-$3620) and $327(95%CI:
$279-$375), and those of obese patients were $5720(95%CI:$5314-$6129) and
$699(95%CI:$608-$790), respectively. Obese patients had 38% higher medical cost
and 53% higher lost productivity costs after adjusting for other study variable.Ad-
ditional medical costs attributable to obesity were calculated at $1087 (95%CI:$687-
$1487) and lost productivity costs attributable to obesity were $279(95%CI:$191-$368).
CONCLUSIONS: The economic burden of asthma among US adults is substantial
which is only further amplified by the presence of obesity. This study highlights the
importance of obesity control to reduce the cost of treating asthma patients and
enhance productivity.
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OBJECTIVES: The objective is to describe the healthcare resource utilization and
cost patterns associated with severe uncontrolled allergic asthma, based on data
from Dutch patients collected in the EXPERIENCE study. METHODS: EXPERIENCE
was a prospective, open-label, observational, multicenter, multicountry study in
patients with severe persistent allergic asthma treated with omalizumab. The
Global Evaluation of Treatment Effectiveness (GETE) was used to evaluate patient
response. Healthcare resource use and number of exacerbations were captured for
one year prior to the start of the study for all patients and continued for 104 weeks
until end of the study. Hospitalizations, specialist visits and medications were
included in this analysis for year before study and first year of study. Unit cost
prices taken from 2010. RESULTS: A total of 154 subjects were included in ITT
population. There were 2.5 clinically significant (CS) exacerbations/patient year
prior compared to 0.90 CS exacerbations/patient for year of study on omalizumab.
The total number of CS severe (CSS) exacerbation was 0.95 CCS exacerbations/
patient for year prior and 0.26 CSS exacerbations/patient for year of study. The
results indicate that patients in this study have an average cost of €4257/patient in
the year prior to the study and €2583/patient cost during the study year, excluding
omalizumab costs. The biggest cost drivers are hospitalization, work days lost and
other asthma medications. The total omalizumab costs were €12,652/patient plus
€1,171/patient for administration cost. CONCLUSIONS: This study reflects real life
clinical practice and associated costs for omalizumab treatment of severe allergic
asthma patients. It indicates a reduction in CS and CSS exacerbation rates of 64%
and 73%, respectively associated with a 40% reduction in treatment costs when
using omalizumab. Keeping in mind the study limitations associated with the
observational setting, it provides estimated costs for patients with severe uncon-
trolled allergic asthma based on ‘real-world’ Dutch practice patterns.
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OBJECTIVES: To develop a self-administered patient reported outcome (PRO) in-
strument to evaluate patients’ experience of early morning symptoms of Chronic
Obstructive Pulmonary Disease (COPD). METHODS: A literature review and inter-
views with six clinical experts were performed to identify concepts for the evalu-
ation of early morning symptoms of COPD and to develop a focus group discussion
guide. Four focus groups were conducted with a total of 27 COPD patients who
experienced COPD symptoms at night or in the early morning. Qualitative data was
analyzed using ATLAS.ti to identify key concepts and patient terminology which
were then used to create a conceptual framework and to generate items and re-
sponse options for the new PRO instrument. One-on-one cognitive debriefing in-
terviews were conducted with 10 COPD patients to assess item readability, com-
prehensiveness, and content validity. RESULTS: Focus group participants had a
mean age of 68.1 years, were 51.9% female, and had a range of COPD severity levels:
7.4% GOLD I (mild), 55.6% GOLD II (moderate), 14.8% GOLD III (severe), 22.2% GOLD
IV (very severe). Most of the participants experienced COPD symptoms in the early
morning (n25, 92.6%). Patients noted symptoms such as cough and impacts such
as restricted morning activities. Cognitive debriefing interviews demonstrated that
the items were comprehensive, relevant and interpreted as intended. A few items
were edited to improve clarity based on feedback from the patients. CONCLUSIONS:
The Early Morning Symptoms of COPD Instrument (EMSCI) is a PRO instrument
developed to evaluate the full range of early morning symptoms of COPD. The
instrument was developed based on patients’ experiences to support content va-
lidity. The EMSCI can be used to characterize COPD patients’ experience of early
morning symptoms for clinical decision making and for the evaluation of new
treatments.
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OBJECTIVES: Hospital-at-home programs for COPD exacerbations aim to provide
care efficiently by shortening or avoiding hospital admissions. The objective was to
quantify Dutch patient and informal caregiver preferences for different aspects of
hospital-at-home. METHODS: In a discrete-choice experiment, respondents made
14 choices between regular hospital admission (7 days) and two programs in which
3 hospital days were followed by a 4-day treatment at home. The home treatment
was described by a set of attributes (see results). Hospital treatment was constant
across choice sets. Respondents were patients and their informal care givers who
participated in an RCT on the cost-effectiveness of hospital-at-home versus regular
hospital care. The data were analyzed in latent-class conditional logit models,
which allowed for heterogeneity across groups. RESULTS: A total of 202 question-
naires were returned. 25% of patients and caregivers always opted for hospital
treatment, 46% always chose hospital-at-home. For both groups, the best fit was
provided by a model with four latent classes, depending on preference for hospital
and caregiver burden. All attributes had the expected sign and a significant effect
on choices, except for number of home visits. Attribute levels with the strongest
impact were hospital preference (for patients, coefficients (depending on class):
-5.62 to 3.3), a 5h/day caregiver burden (-3.5 to -0.11) and co-payment of €100
(1.11). Also influential were specialized training for the homecare nurse (0.52), visits
by many different nurses (-0.43), high readmission risk (-0.41), GP instead of hos-
pital as contact for emergencies (-0.63), €50 co-payment (-0.48), 3h/day caregiver
burden (-0.32), medium readmission risk (-0.24). Results were similar for informal
care givers. CONCLUSIONS: A considerable proportion of patients and caregivers
have a fixed preference for either admission or hospital-at-home, regardless of the
specifics of the program. When choosing between hospital-at home programs,
co-payments and the burden on informal caregivers are the principal attributes.
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OBJECTIVES: The Asthma Life Impact Scale (ALIS) is a disease-specific measure
used to assess the quality of life of people with Asthma. It was developed in parallel
in the UK and US and has proven to be acceptable to patients, to have good psy-
chometric properties and to be unidimensional. The objective of this study was to
adapt and validate the ALIS for use in Italy and Russia. METHODS: The dual panel
methodology was used to translate the ALIS for both cultures. Patient interviews
were conducted to test the new language versions to ensure their face and content
validity. A test-retest postal survey was conducted in both countries to assess the
psychometric properties of the new adaptations.RESULTS:The translation process
proved straightforward. Cognitive debriefing interviews conducted in Italy (n15)
and Russia (n9) indicated that patients found the new versions of the ALIS easy to
complete and relevant. Validation data were available from postal surveys in Italy
(n61) and Russia (n71). Both new versions of the ALIS had good internal consis-
tency (0.92) and high test-retest correlation coefficients (Italian  0.86; Russian 
0.94) indicating good reproducibility. The Russian ALIS showed strong correlations
with a measure of fatigue (CAFS; 0.87) and sleep (CASIS; 0.85). The Italian ALIS had
a moderate correlation with the Nottingham Health Profile Energy level scale (0.63).
Both adaptations of the ALIS were able to distinguish between patients based on
their self-rated general health and asthma severity. CONCLUSIONS: The ALIS was
successfully adapted for use in Italy and Russia. The psychometric properties of
these new adaptations matched those of the original UK and US versions. The new
instruments represent valid and reliable tools for measuring QoL in international
clinical trials and for use in routine clinical practice.
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OBJECTIVES: Conceptual Models (CM) are useful for characterising domains of
Symptoms, Functioning and Treatment Satisfaction. Previously a Conceptual
Model (CM) of asthma was developed and relevance to patients confirmed through
qualitative interviews with 15 asthmatic adults. The aim of this research was to
test the model in adolescents.METHODS:Twenty semi-structured interviews were
conducted with asthmatic adolescents (aged 12-16) in the US. Cards were used to
elicit feedback from the patients on their understanding and experience of differ-
ent concepts included in the CM (symptoms and functioning/disability). Patients
used the cards to rank the importance of symptoms and impacts. Treatment sat-
isfaction was also discussed and the Asthma Control Test (ACT) completed.
RESULTS:Based on the ACT 40% (8/20) of adolescents had poorly controlled asthma
compared with 13% (2/15) of adults in the previous study. Most adolescents re-
ported experiencing all four core symptoms of asthma; breathlessness (n20), tight
chest (n19), cough (n18) and wheeze (n20). Additional symptoms reported by
the adolescents were light-headedness (n7), shaking (n6), congestion (n5),
feeling as if about to pass out (n2), vomiting (n2) and an uncomfortable feeling
in the ribcage (n2). Breathlessness was the most important and bothersome
symptom for both adolescents and adults. The functioning/disability concepts rel-
evant to adolescents were the same as for adults. ‘Spending time with friends/
family’ was the impact ranked as most important by adolescents (n5). Under-
standing of terms and definitions was good for all core symptoms and impacts. The
term ‘rescue inhaler’ was not familiar to a minority (3/12, 25%) of younger
adolescents. CONCLUSIONS:Qualitative analysis of the interviews found evidence
supporting all concepts in the CM. New symptoms reported by adolescents were
distal symptoms experienced due to poorly controlled asthma or rescue medica-
tion overuse. No changes to the CM for asthma are needed for adolescents.
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OBJECTIVES: The Living with Chronic Obstructive Pulmonary Disease (LCOPD)
scale is a disease-specific measure used to assess quality of life of people with
COPD. The measure was developed in parallel in the UK and US and was shown to
be highly acceptable to patients, unidimensional and have very good psychometric
properties. The objective of this study was to adapt and validate the LCOPD for use
in Italy, Spain and Russia. METHODS: Translated versions were produced using
dual panel methodology. The translated versions were tested with patients to en-
sure face and content validity. Test-retest postal surveys were conducted to estab-
lish internal consistency, reproducibility and construct validity. RESULTS: The
translation process proved successful for the new language versions. Cognitive
debriefing interviews conducted in Italy (n15), Spain (n14) and Russia (n8)
indicated that patients found the new versions of the LCOPD acceptable and easy to
comprehend. Validation data was generated from postal surveys in Italy (n51),
Spain (n142) and Russia (n69). All three versions showed good internal consis-
tency ranging from 0.94-0.95, and good reproducibility was evident from the high
test-retest correlation scores (Italian0.96, Russian0.94, Spanish0.85). The Rus-
sian LCOPD had strong correlations with a measure of fatigue (CAFS; 0.87) and sleep
(CASIS; 0.76). The Spanish LCOPD had a moderate correlation with the CAFS (0.66)
and a strong correlation with the CASIS (0.75). The Italian LCOPD had strong cor-
relations with three of the sub-scales of the Nottingham Health Profile (0.83) and
with the NHP-D (0.86). The new adaptations of the LCOPD were all able to distin-
guish between patients based on their self-rated general health and COPD severity.
CONCLUSIONS: The LCOPD was successfully adapted for use in Italy, Spain and
Russia. These results were similar to those found for the original UK and US ver-
sions.
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OBJECTIVES: The performance of daily activities is a major challenge for people
with chronic obstructive pulmonary disease (COPD). The 65-item Functional Per-
formance Inventory (FPI) was developed to quantify these difficulties in naturalistic
studies and clinical trials. The instrument was based on an analytical framework of
functional status and qualitative interviews; it was reduced to a 32-item short form
(FPI-SF) through a systematic process of item reduction and testing and re-format-
ted for greater clarity and ease of use. This study assessed the content validity of
the FPI-SF. METHODS: Qualitative cognitive interviews were performed with men
and women with COPD recruited through pulmonary clinics in the United States.
Interviews were conducted in-person by a trained interviewer using a semi-struc-
tured interview guide and continued to saturation. Qualitative data analyses in-
cluded the following: 1) comprehensiveness; 2) clarity of instructions, items, and
response options; 3) respondent interpretation of the instructions, items, and re-
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